Network Meta-analysis of Oral Chinese Patent Medicine in Treatment of Primary Osteoporosis

The efficacy of oral proprietary Chinese medicine in the prevention and treatment of primary osteoporosis was systematically evaluated through a network meta-analysis. The computer retrieved the four major Chinese databases of CNKI, VIP, Wang Fang, CBM in China and abroad, as well as the three English databases and Web of Science of Medline, EMbase and Cochrane Library. The search cycle was designed as the database was established until February 15, 2022, and screened randomized controlled trials of export taking proprietary Chinese medicine combined with conventional western medicine for the prevention and treatment of primary osteoporosis according to the system evaluation pre-formulated exclusion criteria. Literature screening and data extraction are completed by at least 2 clinical investigators alone. Bias assessment and mapping of included studies using the Revman software, using the Cochrane Bias Risk Assessment tool, using Stata 16. 0 Software for data acquisition and analysis. In the end, 19 RCTS were included, involving 8 kinds of oral proprietary Chinese medicines (You Gui Pills, Jin Tiange Capsules, Gu Shu Kang Granules, Qiang Bone Capsules, Gu Songbao Granules, Xianling Gu Bao Capsules, Hu Gu Capsules, Zuo Gui Pills). The results of the network meta-study are as follows: (1) in terms of improving clinical efficiency, conventional western medicine combined with Hu Gu Capsules has the best effect; (2) in terms of improving bone density, conventional western medicine combined with Xianling Gu Bao has the best effect. This network meta-analysis provides evidence for the efficacy of the above eight proprietary Chinese medicines in the treatment of patients with POP.